Oculopharyngeal Muscular DystrophySymptoms, Doctors, Treatments, Advances & More
Oculopharyngeal Muscular Dystrophy Overview
Learn About Oculopharyngeal Muscular Dystrophy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Capucine Trollet practices practicing medicine in Paris, France. Ms. Trollet is rated as an Elite expert by MediFind in the treatment of Oculopharyngeal Muscular Dystrophy. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Oculopharyngeal Muscular Dystrophy, Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Distal Arthrogryposis.
George Dickson practices practicing medicine in Egham, United Kingdom. Mr. Dickson is rated as an Elite expert by MediFind in the treatment of Oculopharyngeal Muscular Dystrophy. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Oculopharyngeal Muscular Dystrophy, Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Facioscapulohumeral Muscular Dystrophy (FSHD).
Bernard Brais practices practicing medicine in Montreal, Canada. Mr. Brais is rated as an Elite expert by MediFind in the treatment of Oculopharyngeal Muscular Dystrophy. He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Acute Cerebellar Ataxia, Drug Induced Dyskinesia, Oculopharyngeal Muscular Dystrophy, and Spasticity.
Summary: The goal of this observational study is to explore whether oral health and saliva viscosity and composition in Oculopharyngeal Muscular Dystrophy (OPMD) is different from control subjects. The main questions it aims to answer are: Do swallowing disturbances in OPMD adversely affect oral health? Is saliva thickness (viscosity) is increased in OPMD? Does saliva in OPMD contains biochemical markers o...
Summary: Subjects who have enrolled in the oculopharyngeal muscular dystrophy (OPMD) natural history study (Study BNTC-OPMD-NH-001) and have completed at least 6 months of follow up in Study BNTC-OPMD-NH-001 may be eligible to participate in this study, where all subjects will be treated with a single dose of BB-301. BB-301 will be injected directly into the middle pharyngeal constrictor muscle and the inf...